BNP Paribas Financial Markets
ALXN

BNP Paribas Financial Markets’s Alexion Pharmaceuticals ALXN Stock Holding History

BNP Paribas Financial Markets’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-316,030
Closed -$58.1M – 4141
2021
Q2 		$58.1M Buy
316,030
+79,795
+34% +$13.7M 0.08% 285
2021
Q1 		$36.1M Sell
236,235
-264,075
-53% -$40.8M 0.05% 356
2020
Q4 		$78.2M Buy
500,310
+195,156
+64% +$25.1M 0.15% 140
2020
Q3 		$34.9M Sell
305,154
-24,819
-8% -$2.68M 0.05% 355
2020
Q2 		$37M Buy
329,973
+138,338
+72% +$14.7M 0.07% 279
2020
Q1 		$17.2M Sell
191,635
-54,963
-22% -$5.39M 0.04% 460
2019
Q4 		$26.7M Buy
246,598
+106,734
+76% +$11.4M 0.05% 405
2019
Q3 		$13.7M Sell
139,864
-238,146
-63% -$26.8M 0.02% 647
2019
Q2 		$49.5M Buy
378,010
+291,789
+338% +$37.6M 0.1% 224
2019
Q1 		$11.7M Buy
86,221
+34,609
+67% +$4.3M 0.03% 633
2018
Q4 		$5.02M Sell
51,612
-114,256
-69% -$13.5M 0.01% 915
2018
Q3 		$23.1M Sell
165,868
-209,442
-56% -$26.3M 0.03% 485
2018
Q2 		$46.6M Buy
375,310
+241,822
+181% +$28.3M 0.08% 244
2018
Q1 		$14.9M Sell
133,488
-17,315
-11% -$2.07M 0.03% 553
2017
Q4 		$18M Buy
150,803
+15,306
+11% +$1.86M 0.03% 469
2017
Q3 		$19M Buy
135,497
+90,799
+203% +$12.3M 0.05% 363
2017
Q2 		$5.44M Sell
44,698
-144,933
-76% -$16.9M 0.02% 733
2017
Q1 		$23M Buy
189,631
+146,240
+337% +$18.9M 0.06% 321
2016
Q4 		$5.31M Sell
43,391
-150,046
-78% -$18.4M 0.02% 543
2016
Q3 		$23.7M Buy
193,437
+64,374
+50% +$8.29M 0.1% 147
2016
Q2 		$15.1M Sell
129,063
-29,115
-18% -$4.13M 0.07% 210
2016
Q1 		$22M Sell
158,178
-69,359
-30% -$10.2M 0.09% 182
2015
Q4 		$43.4M Buy
227,537
+210,401
+1,228% +$36.8M 0.11% 155
2015
Q3 		$2.68M Sell
17,136
-143,604
-89% -$26.2M 0.01% 790
2015
Q2 		$29.1M Sell
160,740
-60,481
-27% -$10.4M 0.08% 142
2015
Q1 		$38.3M Sell
221,221
-832
-0.4% -$151K 0.11% 119
2014
Q4 		$41.1M Buy
222,053
+22,258
+11% +$4.12M 0.15% 111
2014
Q3 		$33.1M Buy
199,795
+85,302
+75% +$14M 0.03% 230
2014
Q2 		$17.9M Sell
114,493
-91,452
-44% -$14.4M 0.02% 267
2014
Q1 		$32.6M Sell
205,945
-133,255
-39% -$21.2M 0.03% 204
2013
Q4 		$45.1M Buy
339,200
+6,293
+2% +$755K 0.03% 176
2013
Q3 		$38.7M Buy
332,907
+202,845
+156% +$22.3M 0.03% 219
2013
Q2 		$12M Buy
+130,062
New +$12.5M 0.01% 311

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

BNP Paribas Financial Markets's ALXN Position: Q3 2021 in Review

BNP Paribas Financial Markets sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 316,030 shares — an estimated $58.1M sold.

BNP Paribas Financial Markets first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $78.2M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • BNP Paribas Financial Markets reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 316,030 Alexion Pharmaceuticals shares in Q3 2021, an estimated $58.1M.
  • BNP Paribas Financial Markets first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • BNP Paribas Financial Markets's Alexion Pharmaceuticals position peaked at $78.2M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on BNP Paribas Financial Markets's 13F filing for Q3 2021, filed 12 Nov 2021.